## CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, MS RCE, P. O. Box 1450, Alexandria, Virginia 22313-1450, on May 20, 2004.

Jeanne Amour

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Kenneth CHIEN

Serial No.:

09/830,779

Filing Date:

November 30, 2001

For:

A METHOD FOR INHIBITION OF PHOSPHOLAMBAN ACTIVITY FOR THE TREATMENT OF CARDIAC DISEASE AND HEART FAILURE Examiner: P.A. Duffy

Group Art Unit: 1645

# INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

	This Information Disclosure Statement is submitted:
	With the application; accordingly, no fee or separate requirements are required.
$\boxtimes$	Before the mailing of a first Office Action after the filing of a Request for Continued
	Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. §
	1.97 (e)(1) has been provided.
	Within three months of the application filing date or before mailing of a first Office
	Action on the merits; accordingly, no fee or separate requirements are required.
	However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
	After receipt of a first Office Action on the merits but before mailing of a final Office
	Action or Notice of Allowance.
	A fee is required. A check in the amount of is enclosed.
	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached
	to this submission in duplicate.
	A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee
	is believed to be due.
	After mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue fee.
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
	amount of is enclosed.
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
	form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petitions for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing (docketno). However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Date:

Respectfully submitted,

Gregory P. Einhorn Reg. No. 38,440

Morrison & Foerster LLP 3811 Valley Centre Drive, Suite 500 San Diego CA 92130 direct dial 858 720 5133 fax 858 720 5125

Form PTO-1449				Docket Number (220002066200) Application Number (09/830,779)			,779)		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION				Applicant (Kenneth CHIEN)					
	(U	se several sheets if	necessary)		Filing Date (November	30, 2001)	Group Art Unit	(1645)	
					Mailing Date May 20,	2004			
	,		U.S. PA	TEN	Γ DOCUMENTS				
Examiner Initials	Ref. No.	Date	Document No.		Name	Class	Subclass		Date If opriate
	Γ		FOREIGN I	PATI	ENT DOCUMEN	ITS			-X
Examiner Initials	Ref. No.	Date	Document No.		Country	Class	Subclass	Trans YES	lation NO
	1	24 June 1999	WO99/30696	WII	PO		(		
			OTHE	R DO	CUMENTS	(includi	ng author, title, Da	te, Pertinent i	Pages, Etc.)
Examiner Initials	Ref. No.	Title				,			
	2	Koss, K.L 6, 1 Decemb	et al "Phospholambar per 1996, pgs. 1059-1	n: A l 063	Prominent Regulat	or of Myocar	rdial Contracti	ility", Vol	. 79, No.
	3.	Reticulum by	.H., "Influences of In y a Transgenic Appro September 1998, pgs.	oach c	on Cardiac Contrac	he Ca2+ ATI tility", Anna	Pase of the Sails of the New	coplasmic York Aca	c idemy of
	4.		g, et al., "Influence of Pase In Cardiac Myo 06						
	5.		et al.; "Effects of mu Cardiac Myocyte Co						Pase
	6.	Are Essentia	oshihiko, "Amino Ac 1 for Functional Asso 28 January 1994, pps.	ciatio	n with the Ca2+-A	Cytoplasmic ATPase of Sa	Domain of P rcoplasmic Re	hospholar eticulum",	nban Vol.
EXAMIN	IER:				DATE CONS	IDERED:			
EXAMINI conforman	ER: Initia	l if citation consi t considered. Inc	idered, whether or not the clude a copy of this form v	citatio with ne	n conforms with MPE	P 609. Draw a lapplicant.	line through the c	itation if no	t in

## PATENT COOPERATION TREA.

## From the INTERNATIONAL SEARCHING AUTHORITY

# To: McCLAIN, James, W. Attn. MUSICK, ELEANOR M. Brown, Martin, Haller & McClain 1660 Union Street San Diego, CA 92101-2926

# PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL SEARCH REPORT OR THE DECLARATION

1660 Union Street San Diego, CA 92101-2926 UNITED STATES OF AMERICA	(PCT Rule 44.1)
UNITED STATES OF AMERICA	Response due: Aug. 20,2000  Date of mailing  (day/month/year) 20/06/2000
Applicant's or agent's file reference 6627-PC9025	FOR FURTHER ACTION See paragraphs 1 and 4 below
International application No. PCT/US 99/ 25692	International filing date (day/month/year) 02/11/1999
Applicant	· ·
THE REGENTS OF THE UNIVERSITY OF CALIF	ORNIA et al.

IHE.	REGENTS OF THE UNIVERSITY OF CALIFORNIA et al.
1. X	The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.
	Filing of amendments and statement under Article 19: The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):
	When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.
	Where? Directly to the International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Fascimile No.: (41–22) 740.14.35
=	For more detailed instructions, see the notes on the accompanying sheet.
2.	The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.
3.	With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:
	the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.
	no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.
4. Furti	ner action(s): The applicant is reminded of the following:
lf th pric	tly after <b>18 months</b> from the priority date, the international application will be published by the International Bureau.  The applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the publication, must reach the International Bureau as provided in Rules 90 <i>bis</i> .1 and 90 <i>bis</i> .3, respectively, before the international preparations for international publication.
Withi wis	n 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant hes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).
bef	n 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase one all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chanter II.

Name and mailing address of the International Searching Authority

European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Authorized officer

Nina Vercio

## NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

## **INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19**

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international polication. Furthermore, it should be emphasized that provisional protection is available in some States only.

## What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

#### When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

#### Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been fis filed, see below.

#### How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

## What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

## NOTES TO FORM PCT/ISA/220 (continued)

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

# The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

- [Where originally there were 48 claims and after amendment of some claims there are 51]:
   \*Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added.\*
- [Where originally there were 15 claims and after amendment of all claims there are 11]: "Claims 1 to 15 replaced by amended claims 1 to 11."
- [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
  - "Claims 1 to 6 and 14 unchanged, claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or "Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
- [Where various kinds of amendments are made]:
   "Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claims 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

## "Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

## It must be in the language in which the international appplication is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

## Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

## Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide

# PATENT COOPERATION TREA. .

# **PCT**

# INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 6627-PC9025	FOR FURTHER see Notification of (Form PCT/ISA/2	of Transmittal of International Search Report (20) as well as, where applicable, item 5 below.
International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/US 99/25692	02/11/1999	02/11/1998
	RSITY OF CALIFORNIA et al.	
according to Article 18. A copy is being t  This International Search Report consist	_	
Basis of the report		
a. With regard to the language, the	e international search was carried out on the bas nless otherwise indicated under this item.	is of the international application in the
the international search v Authority (Rule 23.1(b)).	was carried out on the basis of a translation of the	ne international application furnished to this
was carried out on the basis of the Contained in the internation of the basis of the Contained in the internation of the basis of the Contained in the internation of the basis of the Contained in the basis of the	nd/or amino acid sequence disclosed in the info ne sequence listing: onal application in written form. emational application in computer readable form o this Authority in written form.	
furnished subsequently to	o this Authority in computer readble form. bsequently furnished written sequence listing do	see set as bound the declarum in the
international application a	as filed has been furnished.	identical to the written sequence listing has been
2. X Certain claims were fou	ınd unsearchable (See Box I).	
3. Unity of Invention is lac	king (see Box II).	
A AAAA		
4. With regard to the title,  \[ \text{X} \] the text is approved as so	ibmitted by the analisant	
	shed by this Authority to read as follows:	
With recard to the abstract.		
<ol> <li>With regard to the abstract,</li> <li>the text is approved as su</li> </ol>	shmitted by the applicant	S = V
the text has been establis	shed, according to Rule 38.2(b), by this Authority a date of mailing of this international search repo	as it appears in Box III. The applicant may, ort, submit comments to this Authority.
6. The figure of the drawings to be publication	ished with the abstract is Figure No.	
as suggested by the appli	cant.	None of the figures.
because the applicant fail	· · · · · · · · · · · · · · · · · · ·	
because this figure better	characterizes the invention.	

## INT-RNATIONAL SEARCH REPORT

ternational Application No PCT/US 99/25692

PCT/US 99/25692 A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/17 A61K A61K47/48 A61P9/04 C07K17/00 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61K C07K IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages Category 5 1-5. X KOSS K L ET AL: "PHOSPHOLAMBAN: A 12 - 17PROMINENT REGULATOR OF MYOCARDIAL CONTRACTILITY" CIRCULATION RESEARCH, vol. 79, no. 6, 1 December 1996 (1996-12-01), pages 1059-1063, XP002053754 ISSN: 0009-7330 the whole document 1-5, DILLMANN W H: "Influences of increased X expression of the Ca2+ ATPase of the 12 - 17sarcoplasmic reticulum by a transgenic approach on cardiac contractility.' ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1998 SEP 16) 853 43-8., XP000914521 page 46, line 47 -page 47, line 16 Patent family members are listed in annex. Further documents are listed in the continuation of box C. Special categories of cited documents : \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled document published prior to the international filling date but "&" document member of the same patent family later than the priority date claimed Date of mailing of the international search report Date of the actual completion of the international search 20/06/2000 5 June 2000

Name and mailing address of the ISA European Patent Office

European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tol. (131...70) 340...2040, Tv. 31 651 epo nl. Authorized officer

C+ ~ : ... A

## INT NATIONAL SEARCH REPORT

ternational Application No PCT/US 99/25692

·		PC1/US 99/25092
C.(Continua	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HE HUAPING ET AL: "Influence of an antisense phospholamban transcribed by an adenoviral vector on Ca-2+ ATPase in cardiac myocytes."  JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 29, no. 6, 1997, page A181  XP000907558  ISSN: 0022-2828 the whole document	1-5, 12-17
<b>X</b>	WO 97 37224 A (MEDICAL RES COUNCIL; BARFORD DAVID (GB); COHEN PHILIP (GB); COHEN) 9 October 1997 (1997-10-09) page 32, line 1 - line 7	1,12,13
X	FR 2 753 722 A (SMITHKLINE BEECHAM LAB) 27 March 1998 (1998-03-27) the whole document	1,12,13
A	TOYOFUKU T ET AL: "Amino acids Glu2 to Ile18 in the cytoplasmic domain of phospholamban are essential for functional association with the Ca2+-ATPase of sarcoplasmic reticulum" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 4, 28 January 1994 (1994-01-28), pages 3088-3094, XP002139384 cited in the application the whole document	1-5, 12-17
A	US 5 652 122 A (PABO CARL ET AL) 29 July 1997 (1997-07-29) the whole document	6-11
Ρ,Χ	MINAMISAWA SUSUMU ET AL: "Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy."  CELL , vol. 99, no. 3, 29 October 1999 (1999-10-29), pages 313-322, XP002139385  ISSN: 0092-8674 the whole document	1-5, 12-17

## INTERNATIONAL SEARCH REPORT

ternational Application No. PCT/US 99/25692

		PCT/US 99/2	25692
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	R	elevant to claim No.
P,X	HE HUAPING ET AL: "Effects of mutant and antisense RNA of phospholamban on SR Ca2+-ATPase activity and cardiac myocyte contractility." CIRCULATION, vol. 100, no. 9, 31 August 1999 (1999-08-31), pages 974-980, XP000907563 ISSN: 0009-7322 the whole document		1-17
Ρ,Χ	WO 99 30696 A (HAIKALA HEIMO ;OVASKA MARTTI (FI); KAHEINEN PETRI (FI); KAIVOLA JU) 24 June 1999 (1999-06-24) the whole document		1,12,13
		į.	
	· ·		
	$\epsilon$		,
		,	
			`
			•
	,		
			•

## INTERNATIONAL SEARCH REPORT

International application No. PCT/US 99/25692

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	emational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. χ	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
·	Although claims $1-5$ , $12-17$ are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.	Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.	Claims Nos.:
	because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)
This Inte	emational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	on Protest
	No protest accompanied the payment of additional search fees.

## INTRNATIONAL SEARCH REPORT

unformation on patent family members

ternational Application No PCT/US 99/25692

	atent document d in search repor	t	Publication date		Patent family member(s)	Publication date
WO	9737224	A	09-10-1997	AU	2172597 A	22-10-1997
				CA	2250826 A	09-10-1997
				EP	0891551 A	20-01-1999
FR	2753722	A	27-03-1998	WO	9813518 A	02-04-1998
US	5652122	Α	29-07-1997	US	5674980 A	07-10-1997
		•		US	5804604 A	08-09-1998
				US	5670617 A	23-09-1997
			4	US	5747641 A	05-05-1998
				AT	142266 T	15-09-1996
				AU	658818 B	04-05-1995
				AU	7182991 A	24-07-1991
				CA	2071214 A	22-06-1991
			•	DE	69028412 D	10-10-1996
				DE	69028412 T	27-03-1997
	-			DK	506884 T	04-11-1996
				EP	0506884 A	07-10-1992
				ES	2091916 T	16-11-1996
				GR	3021474 T	31-01-1997
				WO	9109958 A	11-07-1991
				AT	173016 T	15-11-1998
	-			AU	667244 B	14-03-1996
				AU	5083293 A	15-03-1994
				CA	2135642 A	03-03-1994
				DE	69321962 D	10-12-1998
				DE	69321962 T	01-07-1999
				DE	656950 T	14-03-1996
				EP	0656950 A	14-06-1995
				EP	0903408 A	24-03-1999
				ES	2123062 T	01-01-1999
			,	FI	945248 A	05-01-1995
				JP	2869396 B	10-03-1999
			,	JP	10033186 A	10-02-1998
				JP	2702285 B	21-01-1998
				JP	7503617 T	20-04-1995
				KR	153027 B	15-10-1998
				NO ·	944273 A	17-02-1995
			•	NZ	255831 A	24-04-1997
				WO .	9404686 A	03-03-1994
WO	9930696	Α	24-06-1999	AU	1565599 A	05-07-1999
				US	5968959 A	19-10-1999